These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 27058179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A, Gómez-Lim MA, Weiss-Steider B, Hernández-Montes J, Huerta-Yepez S, Rangel-Santiago JF, Santiago-Osorio E, Mora García Mde L.
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [Abstract] [Full Text] [Related]

  • 4. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, Wang J, Zhao B, Li N, Jiang M.
    Virus Res; 2016 Jul 15; 220():97-103. PubMed ID: 27107614
    [Abstract] [Full Text] [Related]

  • 5. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C, Dey B, Wahiduzzaman M, Singh N.
    Vaccine; 2012 Aug 03; 30(36):5417-24. PubMed ID: 22717329
    [Abstract] [Full Text] [Related]

  • 6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 7. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 8. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M, Wang D, Li Z, Song S, Kong X, Mo X, Yang Y, He M, Li Z, Huang B, Lin Z, Pan H, Zheng Q, Yu H, Gu Y, Zhang J, Li S, Xia N.
    Emerg Microbes Infect; 2018 Sep 26; 7(1):160. PubMed ID: 30254257
    [Abstract] [Full Text] [Related]

  • 9. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.
    Hassan SW, Waheed MT, Müller M, Clarke JL, Shinwari ZK, Lössl AG.
    Hum Vaccin Immunother; 2014 Sep 26; 10(10):2975-82. PubMed ID: 25483463
    [Abstract] [Full Text] [Related]

  • 10. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.
    Mol Immunol; 2015 Apr 26; 64(2):295-305. PubMed ID: 25575128
    [Abstract] [Full Text] [Related]

  • 11. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
    Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L.
    J Virol; 2003 Apr 26; 77(8):4635-45. PubMed ID: 12663770
    [Abstract] [Full Text] [Related]

  • 12. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A, Bolhassani A, Javadi G, Noormohammadi Z.
    Sci Rep; 2019 Oct 23; 9(1):15225. PubMed ID: 31645650
    [Abstract] [Full Text] [Related]

  • 13. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA.
    Antivir Ther; 2009 Oct 23; 14(8):1125-37. PubMed ID: 20032542
    [Abstract] [Full Text] [Related]

  • 14. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.
    Bian T, Wang Y, Lu Z, Ye Z, Zhao L, Ren J, Zhang H, Ruan L, Tian H.
    Mol Cancer Ther; 2008 May 23; 7(5):1329-35. PubMed ID: 18483320
    [Abstract] [Full Text] [Related]

  • 15. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.
    Clin Vaccine Immunol; 2007 Oct 23; 14(10):1285-95. PubMed ID: 17687110
    [Abstract] [Full Text] [Related]

  • 16. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    Virology; 2007 Feb 20; 358(2):266-72. PubMed ID: 17010405
    [Abstract] [Full Text] [Related]

  • 17. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.
    Ryding J, Dahlberg L, Wallen-Öhman M, Dillner J.
    J Gen Virol; 2007 Mar 20; 88(Pt 3):792-802. PubMed ID: 17325351
    [Abstract] [Full Text] [Related]

  • 18. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X, Zhang T, Liu H, Hao Y, Liao G, Xu X.
    Hum Vaccin Immunother; 2018 Mar 20; 14(8):2025-2033. PubMed ID: 29683766
    [Abstract] [Full Text] [Related]

  • 19. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [Abstract] [Full Text] [Related]

  • 20. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW, Ye ZM, Lu ZH, Jao R, Bian T, Zhao L, Ruan L.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun 16; 20(2):33-7. PubMed ID: 16816859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.